These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 342317)

  • 1. A placebo-controlled dose-response study of the reactogenicity and immunogenicity of a cold-adapted recombinant A/Victoria/3/75 (H3N2) live influenza virus candidate vaccine in healthy volunteers.
    Hrabar A; Vodopija I; André FE; Mitchell JR; Maassab HF; Hennessy AV; Davenport FM
    Dev Biol Stand; 1977 Jun 1-3; 39():53-60. PubMed ID: 342317
    [No Abstract]   [Full Text] [Related]  

  • 2. HI antibody response in volunteers vaccinated with live influenza A/New Jersey/76 vaccine.
    Ikić D; Smerdel S; Manhalter T; Pasini N; Delimar N
    Dev Biol Stand; 1977 Jun 1-3; 39():67-71. PubMed ID: 342319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
    Lee KH; Seo SU; Song JM; Lee CM; Kim HA; Seong BL
    Vaccine; 2006 Mar; 24(11):1966-74. PubMed ID: 16343703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials with a new influenza subunit vaccine in adults and children.
    Kunz C; Hofmann H; Bachmayer H; Liehl E; Moritz AJ
    Dev Biol Stand; 1977 Jun 1-3; 39():297-302. PubMed ID: 342311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults.
    Keitel WA; Cate TR; Nino D; Huggins LL; Six HR; Quarles JM; Couch RB
    J Infect Dis; 2001 Jan; 183(2):329-332. PubMed ID: 11110645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of influenza A/New Jersey/76 virus strain, preparation of live vaccine and vaccine reactogenicity in volunteers.
    Ikić D; Pasini N; Hećimović M; Juzbasić M; Smerdel S; Rajner N; Jelavić V
    Dev Biol Stand; 1977 Jun 1-3; 39():61-5. PubMed ID: 342318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
    Safdar A; Rodriguez MA; Fayad LE; Rodriguez GH; Pro B; Wang M; Romaguera JE; Goy AH; Hagemeister FB; McLaughlin P; Bodey GP; Kwak LW; Raad II; Couch RB
    J Infect Dis; 2006 Nov; 194(10):1394-7. PubMed ID: 17054068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuated ts-recombinants of influenza A/USSR/77 (H1N1) virus obtained by crossing with the cold-adapted donor A/Leningrad/134/57 (H2N2) virus.
    Polezhaev FI; Garmashova LM; Koval TA; Taranova GP; Topuriya NV; Aleksandrova GI
    Acta Virol; 1982 Jul; 26(4):221-6. PubMed ID: 6127928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties of A/Victoria/3/75 recombinants: development of an attenuated strain RIT 4050.
    Lobmann M; Delem A; Jovanović D
    Dev Biol Stand; 1977 Jun 1-3; 39():43-6. PubMed ID: 604127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
    Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
    J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.
    Belshe RB; Gruber WC; Mendelman PM; Mehta HB; Mahmood K; Reisinger K; Treanor J; Zangwill K; Hayden FG; Bernstein DI; Kotloff K; King J; Piedra PA; Block SL; Yan L; Wolff M
    J Infect Dis; 2000 Mar; 181(3):1133-7. PubMed ID: 10720541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinico-immunologic and allergologic studies with the inactivated influenza virus vaccine purified and concentrated by gradient centrifugation.
    Subbotina TI; Tenkova TV; Sidorova LV; Shpilyuk GF; Drinevsky VP; Voitsekhovskaya EM; Konstantinov VK; Sominina AA
    Acta Virol; 1988 Nov; 32(6):494-502. PubMed ID: 2906221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.
    King JC; Treanor J; Fast PE; Wolff M; Yan L; Iacuzio D; Readmond B; O'Brien D; Mallon K; Highsmith WE; Lambert JS; Belshe RB
    J Infect Dis; 2000 Feb; 181(2):725-8. PubMed ID: 10669363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.
    Vesikari T; Karvonen A; Smith HM; Dunning A; Razmpour A; Saville MK; Gruber WC; Forrest BD
    Pediatrics; 2008 Mar; 121(3):e568-73. PubMed ID: 18299305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological, genetic and biochemical characterization of a cold-adapted recombinant A/Victoria/3/75 virus and its evaluation in volunteers.
    Maassab HF; Cox NJ; Murphy BR; Kendal AP
    Dev Biol Stand; 1977 Jun 1-3; 39():25-31. PubMed ID: 604106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Live influenza A/Victoria/75 (H3N2) virus vaccines: reactogenicity, immunogenicity, and protection against wild-type virus challenge.
    Cate TR; Couch RB
    Infect Immun; 1982 Oct; 38(1):141-6. PubMed ID: 7141686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Live cold-adapted influenza A vaccine produced in Vero cell line.
    Romanova J; Katinger D; Ferko B; Vcelar B; Sereinig S; Kuznetsov O; Stukova M; Erofeeva M; Kiselev O; Katinger H; Egorov A
    Virus Res; 2004 Jul; 103(1-2):187-93. PubMed ID: 15163508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.